�������

I am Peter H. Schub Professor and Chair of the Department of Psychiatry at �����о��� Grossman School of Medicine, and I am the Director of the �����о��� Langone Health Center for Precision Medicine in Alcohol Use Disorder and PTSD. My primary research focus revolves around the utilization of genomic and circuit biomarkers to forward the field of precision medicine specifically addressing alcohol use disorder and PTSD. Currently, I am the Principal Investigator on several projects supported by NIH and the Department of Defense. These include an NIH P01 center grant focused on harnessing biomarkers to customize treatments for alcohol use disorder comorbid with PTSD; a Department of Defense Center grant dedicated to enriching our understanding of clinical subtypes and their endophenotypes for military service–related PTSD and thus refining precision psychiatry; and an NIH R01 for enhancing precision medicine for Gabapentin treatment of AUD through system pharmacology. Furthermore, I am Co-Principal Investigator for a DARPA project whose focus is to not only build resilience in healthcare workers, but to do so by harnessing wellness platforms and advanced computational modeling. My recent research achievements include the discovery of genomic, metabolomic, and proteomic biomarkers for PTSD diagnostic screening for veterans, the use of speech-based biomarkers for diagnostic screening of PTSD in veterans, identifying pre-deployment genomic, metabolomic, and proteomic biomarkers to predict PTSD in active military personnel, and employing advanced computational machine learning methods for building causal models of clinical features. This last advancement aids in identifying likely responders to the Extended-Release Gabapentin Enacarbil treatment for alcohol use disorder.